| Literature DB >> 33708914 |
Ruihui Lu1, Ran Chu1, Na Gao1, Guiyang Li1, Haiyang Tang1, Xinxin Zhou1, Xiangxin Lan1, Shuyi Li1,2, Xi Zhang1, Yintao Xu1, Yuyan Ma1.
Abstract
BACKGROUND: To develop the risk prediction model of intraoperative massive blood loss in placenta previa with placenta increta or percreta.Entities:
Keywords: Placenta previa; intraoperative massive blood loss; placenta increta; placenta percreta; risk prediction model
Year: 2021 PMID: 33708914 PMCID: PMC7944278 DOI: 10.21037/atm-20-5160
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Flowchart of included patients. ROC, receiver operating characteristic.
Baseline characteristics
| Characteristics | Development group (n=179) | Validation group (n=81) | P value |
|---|---|---|---|
| Preoperative characteristics | |||
| Age at delivery (years) | 32 [29–36] | 35 [31–37] | 0.002 |
| Gravidity | 3 [3–4] | 4 [3–5] | 0.154 |
| Parity | 1 [1–1] | 1 [1–2] | <0.001 |
| History of dilatation and curettage of uterus | 1 [0–2] | 1 [0–1] | 0.867 |
| Previous caesarean section | 0.003 | ||
| ≤1 | 142 (79.3) | 50 (61.7) | |
| >1 | 37 (20.7) | 31 (38.3) | |
| Preoperative HGB level (g/L) | 0.456 | ||
| <100 | 66 (36.9) | 26 (32.1) | |
| ≥100 | 113 (63.1) | 55 (67.9) | |
| Gestational age (days) | 255 [244–260] | 253 [245–261] | 0.769 |
| Obstetric complications | |||
| Preeclampsia | 2 (1.1) | 4 (4.9) | 0.009 |
| Gestational diabetes mellitus | 17 (9.5) | 11 (13.6) | 0.325 |
| Placenta previa classification | 0.118 | ||
| Marginal placenta previa | 22 (12.3) | 17 (21.0) | |
| Partial placenta previa | 4 (2.2) | 3 (3.7) | |
| Complete placenta previa | 153 (85.5) | 61 (75.3) | |
| Prenatal ultrasound results | |||
| Retroplacental myometrial thickness <1 mm | 127 (70.9) | 55 (67.9) | 0.619 |
| Vascular lacunae within the placenta | 107 (59.8) | 48 (59.3) | 0.937 |
| Hypervascularity of uterine-placental margin | 127 (70.9) | 48 (59.3) | 0.063 |
| Irregularity of uterine-bladder interface | 26 (14.5) | 33 (40.7) | <0.001 |
| Hypervascularity of the uterine serosa-bladder wall interface | 43 (24.0) | 34 (42.0) | 0.003 |
| Hypervascularity of cervix | 19 (10.6) | 13 (16.0) | 0.217 |
| Type of PAS | 0.058 | ||
| Placenta increta | 169 (94.4) | 71 (87.7) | |
| Placenta percreta | 10 (5.6) | 10 (12.3) | |
| Emergency cesarean section | 21 (11.7) | 7 (8.6) | 0.457 |
| Surgical characteristics | |||
| Total operation time (min) | 90 [73–120] | 98 [70–124] | 0.635 |
| Length of hospital (days) | 11 [8–17] | 10 [8–20.5] | 0.912 |
| Postoperative Length of hospital (days) | 5 [4–7] | 5 [4–7] | 0.718 |
| Intraoperative blood loss | 1,200 [800–2,500] | 1,800 [1,000–2,500] | 0.050 |
| Intraoperative blood loss ≥2,500 mL | 45 (25.1) | 26 (32.1) | 0.243 |
| Units of PRBC transfused | 4 [4–8] | 6 [4–8] | 0.232 |
| Preoperative BPAA | 46 (25.7) | 20 (24.7) | 0.863 |
| B-Lynch suture | 36 (20.1) | 40 (49.4) | <0.001 |
| Ligation of ascending branch of uterine artery | 32 (17.9) | 15 (18.5) | 0.901 |
| Tourniquet binding the lower uterine segment | 23 (12.8) | 18 (22.2) | 0.055 |
| Hysterectomy | 4 (2.2) | 4 (4.9) | 0.261 |
| Bladder repair | 10 (5.6) | 10 (12.3) | 0.058 |
| Systemic infections | 4 (2.2) | 1 (1.2) | 1.000 |
| Thrombotic complications | |||
| Pulmonary embolism | 1 (0.6) | 0 (0.0) | 1.000 |
| DVT or thrombotic requiring therapy | 0 (0.0) | 1 (1.2) | 0.312 |
| DIC | 2 (1.1) | 1 (1.2) | 1.000 |
| ICU | 2 (1.1) | 2 (2.5) | 0.591 |
Values are median [interquartile range] or n (%). HGB, hemoglobin; PAS, placenta accreta spectrum; PRBC, packed red blood cells; BPAA, balloon placement of abdominal aorta; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; ICU, intensive care unit.
Univariate analysis in the development group
| Characteristics | OR (95% CI) | P value |
|---|---|---|
| Preoperative characteristics | ||
| Age (years) | 1.00 (0.90–1.08) | 0.947 |
| Gestational age (days) | 1.00 (0.98–1.00) | 0.187 |
| Caesarean section >1 | 1.59 (0.72–3.50) | 0.253 |
| History of dilatation and curettage of uterus | 0.87 (0.63–1.21) | 0.412 |
| GDM | 2.28 (0.81–6.41) | 0.117 |
| HGB <100 g/L | 1.05 (0.52–2.12) | 0.884 |
| Placenta previa classification | 1.01 (0.60–1.67) | 0.986 |
| Retroplacental myometrial thinning <1 mm | 1.36 (0.63–2.95) | 0.433 |
| Vascular lacunae within the placenta | 2.58 (1.21–5.52) | 0.014 |
| Hypervascularity of uterine-placental margin | 2.26 (0.97–5.26) | 0.058 |
| Irregularity of uterine-bladder interface | 1.12 (0.44–2.86) | 0.821 |
| Hypervascularity of the uterine serosa-bladder wall interface | 1.89 (0.90–3.99) | 0.094 |
| Hypervascularity of cervix | 2.42 (0.91–6.46) | 0.078 |
| Emergency cesarean section | 4.01 (1.57–10.23) | 0.004 |
| Surgical characteristics | ||
| No preoperative BPAA | 4.68 (1.57−13.91) | 0.006 |
| B-Lynch suture | 0.84 (0.37–1.92) | 0.683 |
| Ligation of ascending branch of uterine artery | 0.83 (0.35–1.95) | 0.668 |
| Tourniquet binding the lower uterine segment | 0.47 (0.19–1.17) | 0.103 |
GDM, gestational diabetes mellitus; HGB, hemoglobin; BPAA, balloon placement of abdominal aorta; OR, odds ratio; CI, confidence interval.
Multivariate logistic regression models in the development group
| Variables | Regression coefficients | OR (95% CI) | P value |
|---|---|---|---|
| Model A | |||
| Vascular lacunae within the placenta | 1.292 | 3.64 (1.45–9.14) | 0.006 |
| Hypervascularity of uterine-placental margin | 1.230 | 3.42 (1.26–9.27) | 0.016 |
| Hypervascularity of cervix | 1.155 | 3.17 (1.08–9.33) | 0.036 |
| Emergency cesarean section | 2.376 | 10.76 (3.31–34.91) | <0.001 |
| Model B | |||
| Vascular lacunae within the placenta | 1.444 | 4.24 (1.97–21.66) | 0.005 |
| Hypervascularity of uterine-placental margin | 1.877 | 6.53 (1.55–11.61) | 0.002 |
| Hypervascularity of the uterine serosa-bladder wall interface | 1.337 | 3.81 (1.23–11.77) | 0.020 |
| Hypervascularity of cervix | 1.584 | 4.87 (1.35–17.62) | 0.016 |
| Emergency cesarean section | 2.449 | 11.57 (3.22–41.67) | <0.001 |
| No preoperative BPAA | 2.830 | 16.95 (4.05–70.92) | <0.001 |
BPAA, balloon placement of abdominal aorta; OR, odds ratio; CI, confidence interval.
Figure 2Nomograms to predict the probability of intraoperative massive blood loss in the patient with placenta increta or percreta. The nomogram can be applied by following procedures: (I) obtain the points corresponding to each predictor, (II) the sum of the points is recorded as the total score, and (III) the predicted risk corresponding to the total score is the probability of intraoperative blood loss ≥2,500 mL in placenta increta and percreta.
Figure 3ROC curves and calibration plots. (A) Development group, AUC of model A is 0.732 (95% CI: 0.655–0.809), AUC of model B is 0.839 (95% CI: 0.781–0.897), P value is less than 0.001 (A vs. B); (B) validation group, AUC of model A is 0.736 (95% CI: 0.626–0.845), AUC of model B is 0.829 (95% CI: 0.742–0.916), P value is 0.007 (A vs. B); (C) model A in development group, (D) model B in development group, (E) model A in validation group, (F) model B in validation group. Calibration curves were applied to evaluate the calibration of the models. The horizontal axis is the predicted probability provided by the model, and the vertical axis is the observed incidence of intraoperative blood loss ≥2,500 mL. The 45-degree line is the actual probability. When the prediction probability of model is closer to the 45-dgree line, the prediction model has better calibration power. When the solid line is below the 45-dgree line, the prediction probability provided by the model is higher than the actual probability (overprediction); if the solid line is above the 45-dgree line, the prediction probability provided by the model is lower than the actual probability (underprediction).
Figure 4Decision curves. (A) Development group, (B) validation group. Draw the decision curve with the net benefit as vertical axis and the threshold probability as horizontal axis. The solid black line represents the net benefit when all patients are considered as not developing outcome (intraoperative blood loss ≥2,500 mL). The solid grey line represents the net benefit when all patients are considered as developing outcome. The preferred model is the model with the highest net benefit.